JPH05507924A - 免疫反応性化合物 - Google Patents

免疫反応性化合物

Info

Publication number
JPH05507924A
JPH05507924A JP91511093A JP51109391A JPH05507924A JP H05507924 A JPH05507924 A JP H05507924A JP 91511093 A JP91511093 A JP 91511093A JP 51109391 A JP51109391 A JP 51109391A JP H05507924 A JPH05507924 A JP H05507924A
Authority
JP
Japan
Prior art keywords
immunoreactive
igm
compound according
iga
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP91511093A
Other languages
English (en)
Japanese (ja)
Inventor
ボス，エボ・シブレン
ブーン，ペトルス・ヨハネス
Original Assignee
アクゾ・エヌ・ヴエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクゾ・エヌ・ヴエー filed Critical アクゾ・エヌ・ヴエー
Publication of JPH05507924A publication Critical patent/JPH05507924A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP91511093A 1990-07-03 1991-06-28 免疫反応性化合物 Pending JPH05507924A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP90201781 1990-07-03
EP90201781.3 1990-07-03
PCT/EP1991/001223 WO1992000763A1 (fr) 1990-07-03 1991-06-28 Compose immunoreactif

Publications (1)

Publication Number Publication Date
JPH05507924A true JPH05507924A (ja) 1993-11-11

Family

ID=8205056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP91511093A Pending JPH05507924A (ja) 1990-07-03 1991-06-28 免疫反応性化合物

Country Status (7)

Country Link
EP (1) EP0537222A1 (fr)
JP (1) JPH05507924A (fr)
KR (1) KR930701201A (fr)
CA (1) CA2086531A1 (fr)
FI (1) FI925804A0 (fr)
HU (1) HUT63343A (fr)
WO (1) WO1992000763A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU556548B2 (en) * 1980-03-03 1986-11-06 Milton David Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
CA1168150A (fr) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Conjugats d'albumine et d'agents therapeutiques
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
EP0293524A1 (fr) * 1987-06-02 1988-12-07 Vasocor Immunoessai de plaque athérosclérotique
EP0295719A3 (fr) * 1987-06-19 1989-12-20 The Agouron Institute Antigène SM-D, le clonant de l'antigène SM-D et la détection de lupus érythémateux systémique en utilisant cet antigène SM-D
ATE82136T1 (de) * 1987-08-10 1992-11-15 Miles Inc Gereinigtes igm.
US4937183A (en) * 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
EP0398872A1 (fr) * 1988-02-12 1990-11-28 HighTech Receptor AB Substance de liaison d'immunoglobuline, sous-fragments, leur procede de preparation, kit de reactif et organismes de liaison d'immunoglobuline
US4983529A (en) * 1988-06-10 1991-01-08 Abbott Laboratories Immunoassay for HIV-I antigens using F(AB')2 fragments as probe
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
WO1990011091A1 (fr) * 1989-03-27 1990-10-04 Centocor, Inc. COMPOSITIONS SERVANT A STABILISER DES ANTICORPS D'IMMUNOGLOBULINE IgM

Also Published As

Publication number Publication date
HU9204170D0 (en) 1993-04-28
WO1992000763A1 (fr) 1992-01-23
KR930701201A (ko) 1993-06-11
FI925804A (fi) 1992-12-21
EP0537222A1 (fr) 1993-04-21
CA2086531A1 (fr) 1992-01-04
FI925804A0 (fi) 1992-12-21
HUT63343A (en) 1993-08-30

Similar Documents

Publication Publication Date Title
JP2942356B2 (ja) 毒素および薬剤を含む治療用複合体
AU636872B2 (en) Cross-linked antibodies and processes for their preparation
EP0871673B1 (fr) Anticorps bispecifiques dont la capacite de fixation est inhibee de facon reversible par une groupe fissible par exposition a l'energie electromagnetique
EP0602290B1 (fr) Antigène de surface du virus de l'hépatite B conjugué à des anticorps et utilisation d'un tel conjugué
JPS61500789A (ja) モノクロ−ナル抗−ヒト乳癌抗体
JPS61227532A (ja) 抗体ハイブリツド分子およびその製造方法
EP1132097A2 (fr) Proteine serique et cellulaire d'ancrage et conjugues
EP0815872A2 (fr) Composés de ciblage
JPH021129B2 (fr)
US6136313A (en) Processes and intermediates for synthetic antibody derivatives
US6509451B1 (en) Cross-linked antibodies and processes for their preparation
US4843147A (en) Anhydrous enhanced coupling of proteins
JPH05507924A (ja) 免疫反応性化合物
US8124743B2 (en) Purification of a bivalently active antibody using a non-chromatographic method
AU598426B2 (en) Anhydrous enhanced coupling of proteins
Chaudri et al. Dual specificity antibodies using a double‐stranded oligonucleotide bridge
JP3836429B2 (ja) 規定した化学量論の結合体
AU8063591A (en) Immunoreactive compound
EP0650735A2 (fr) Kit et méthode de préciblage
Wines et al. The Fab/c fragment of IgG produced by cleavage at cyanocysteine residues
Sletten et al. On the Frequency of Valine in Position 2 of the VkIII Subgroup
JPH0428719B2 (fr)
AU678474B2 (en) Kit and method for pretargeting
WO1996000087A2 (fr) Materiel de preciblage et nouveaux conjugues de preciblage
Singh et al. Studies on adjuvants for contraceptive vaccines